Get a Quote

CEFIDEROCOL SULFATE TOSYLATE
CAS NO.: 2135543-94-9
Chemical Formula: C118H138Cl3N21O47S11
Molecular Weight: 3061.6000
DMF&GMP status: Please contact us for more details.
Description:
Cefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics. Unlike other agents in this category, cefiderocol is a siderophore able to undergo active transport into the bacterial cell through iron channels. It represents a significant addition to antibacterial treatment option as it has proven to be effective *in vitro* against multidrug resistant strains including extended spectrum β-lactamase producers and carbapenemase producing bacteria. Cefiderocol was granted designation as a Qualified Infectious Disease Product and granted priority review status by the FDA on November 14, 2019. It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available. This indication was supported by a positive clinical trial composed of 448 patients with complicated urinary tract infections which demonstrated a 72.6% rate of symptom resolution and bacterial eradication with cefiderocol compared to 54.6% with the comparator, imipenem/cilastatin. A concern noted in the trial was a 0.3% higher rate of all cause mortality, the cause of which has not been determined.

**The products protected by patents in this product catalog are used for laboratory analysis, research and development, and cannot be sold to any country or region with patent protection and for commercial purpose. If the resulting patent infringement risks and responsibilities will be borne by the buyer.
Approvals
Active Ingredient Dosage Form; Route Strength Proprietary Name Applicant
CEFIDEROCOL SULFATE TOSYLATEPOWDER;INTRAVENOUSEQ 1GM BASE/VIALFETROJASHIONOGI INC
Patent Data
Patent No. Patent Expiration Drug Substance Claim Drug Product Claim Patent Use Code
923865711/19/2031DSDPU-282
994998209/03/2035DP
1000475009/03/2035DSDP
Exclusive Data
Exclusivity Code Exclusivity Expiration
I-844 09/25/2023
NCE 11/14/2024
NCE *GAIN 11/14/2029